Hilal SUSAM ŞEN, Belen ATEŞ, Pınar YILMAZBAŞ, Süheyla OCAK, Hale KIRIMLIOĞLU, Selim GÖKÇE, Koray ACARLI

Successful treatment of pediatric post-liver transplant Kaposi’s sarcoma with paclitaxel

Background. Kaposi’s sarcoma (KS) is a complication of immunosuppressive therapy for transplant recipients. Unlike adult recipients, KS in pediatric organ transplantation is quite rare. Treatment is usually withdrawal of immunosuppression; non-responders often receive chemotherapy. Case. We have reported a child with post-liver transplant visceral KS which has progressed despite withdrawal of immunosuppressive therapy, who has been treated with Paclitaxel for three weeks. KS has regressed completely after four cycles of Paclitaxel.Conclusion. Paclitaxel should be considered as an effective first line treatment option for patients with post-transplant KS.

PDF

___

1.Schneider JW, Dittmer DP. Diagnosis and treatment of Kaposi sarcoma. Am J Clin Dermatol 2017; 18: 529-539.

2.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

3.Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998; 16: 683-691.

4.Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Clin Oncol 1999; 17: 1876-1883.

5.Patel N, Salifu M, Sumrani N, et al. Successful treatment of post-renal transplant Kaposi’s sarcoma with paclitaxel. Am J Transplant 2002; 2: 877-879.

6.Debray D, Baudouin V, Lacaille F, et al; Pediatric Transplantation Working Group of the French Speaking Society of Transplantation. De novo malignancy after solid organ transplantation in children. Transplant Proc 2009; 41: 674–675.

7.Yuksekkaya HA, Arikan C, Yazici A, Baran M, Aydogdu S, Kilic M. Successful treatment of a child having generalized Kaposi’s sarcoma after living donor liver transplantation with conversion to sirolimus. Pediatr Transplant 2009; 13: 375-378.

8.Celtik C, Unüvar A, Aydoğan A, et al. Human herpes virus type 8-associated Kaposi sarcoma in a pediatric liver transplant recipient. Pediatr Transplant 2011; 15: E100-E104.

9.Guba M, Yezhelyev M, Eichhorn ME, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 2005; 105: 4463-4469.

10.Aseni P, Vertemati M, Minola E, et al. Kaposi’s sarcoma in liver transplant recipients: morphological and clinical description. Liver Transpl 2001; 7: 816-823.

11.Penn I. Sarcomas in organ allograft recipients. Transplantation 1995; 60: 1485-1491.

12.Francès C. Kaposi’s sarcoma after renal transplantation. Nephrol Dial Transplant 1998; 13: 2768-2773.

13.Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.

14.Tschachler E. Kaposi sarcoma. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell D, (eds). Fitzpatrick’s Dermatology in General Medicine (7th ed). New York: McGrow-Hill, 2008: 1183-1187.

15.Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxelfor antiangiogenesis. J Hematother Stem Cell Res 2002; 11: 103-118.

16.Saville MW, Lietzau J, Pluda JM, et al. Treatment of HIV-associated Kaposi’s sarcoma with paclitaxel. Lancet 1995; 346: 26-28.

17.Von Roenn JH, Krown SE. Management of AIDS-associated Kaposi’s sarcoma: a multidisciplinary perspective. Oncology (Williston Park) 1998; 12(2 Suppl 3): 1-24.

18.Chao SC, Lee JY, Tsao CJ. Treatment of classical type Kaposi’s sarcoma with paclitaxel. Anticancer Res 2001; 21: 571-573.

19.Marcelin AG, Roque-Afonso AM, Hurtova M, et al. Fatal disseminated Kaposi’s sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transpl 2004; 10: 295-300.

20.Dow DE, Cunningham CK, Buchanan AM. A review of human herpesvirus 8, the Kaposi’s sarcoma-associated herpesvirus, in the pediatric population. J Pediatric Infect Dis Soc 2014; 3: 66-76.